Facial Skin Clinical and Microbial Profiling From Oral Probiotic Supplementation
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Healthy
- Sponsor
- Oriflame Cosmetics AB
- Enrollment
- 109
- Locations
- 1
- Primary Endpoint
- Change from Baseline Antioxidant Level at 8 weeks
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The goal of this double-blind randomized clinical trial is to investigate the effects on the skin from oral intake of probiotic supplements in healthy adult men and women. The main questions it aims to answer are: • Will probiotic supplementation result in beneficial changes to different skin parameters? • Will probiotic supplementation result in alterations in the skin microbiome? Participants will consume the study product daily for 8 weeks and come in for skin measurements at baseline and after 8 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy volunteers
- •Fully informed with the study specifications.
- •Signed consent form prior to commencing the study.
- •Motivated for participation in the study, and available over the full test period.
- •Healthy skin on the face (i.e., absence of psoriasis, eczemas, erythema, oedema, scars, wounds, lesions, or any other type of inflammatory or autoimmune skin condition).
- •Healthy gut (i.e., absence of irritable bowel diseases (IBD), irritable bowel syndrome (IBS), or any other type of inflammatory or autoimmune gut condition).
- •No supplementation with probiotic, prebiotic or synbiotic products 2 weeks prior and/or during the whole study period.
- •No supplementation with niacin (vitamin B3) 2 weeks prior and/or during the whole study period.
- •No significant change in skin care routine (such as injectable cosmetics, skin tanning, etc.) throughout the whole study period.
- •No significant change in the diet throughout the whole study period.
Exclusion Criteria
- •Not fulfilling the inclusion criteria.
- •Pregnant or lactating 3 months prior to study commencement or during the study.
- •Women post menopause.
- •Use of antibiotics at least 4 weeks prior and/or during the whole study period.
- •Sun-tanned facial skin.
- •Participating in another clinical study that could interfere with the present research.
- •Presented health problems or specific medications that could adversely affect the study outcome.
- •Presented any cutaneous hypersensitivity or allergy to cosmetic products.
- •Major surgery on the face one year prior to study commencement.
- •Applied any cleansing, topical or moisturizing product (including all make-up products) to the measurement area the morning of assessments at Oriflame Cosmetic AB.
Outcomes
Primary Outcomes
Change from Baseline Antioxidant Level at 8 weeks
Time Frame: Day 0, Day 56
Skin feature: Antioxidant level Site: Temple/Cheek area Procedure: BioZoom Unit: Arbitrary unit (AU)
Change from Baseline Skin Features (pores, wrinkles, colour, pigmentation and redness) at 8 weeks
Time Frame: Day 0, Day 56
Skin features: Pores, wrinkles, colour, pigmentation and redness Site: Cheek, Temple and Forehead - 3 measurement per area. Thus 9 in total. Procedure: As per WI091 Standard use of the Miravex Antera 3D Camera V1 and TM089 Skin features measurements Using the Antera 3D V1 Unit: Pores: volume (mm3), index, count, volume/count Wrinkles: overall size, depth (mm), width (mm), Texture: Average Roughness (Ra) Colour variation: DeltaE Pigmentation/redness: average level (concentration per unit area), color variation.
Change from Baseline Skin Features (shininess) at 8 weeks
Time Frame: Day 0, Day 56
Skin features: Shininess Site: Entire face Procedure: As per WI044 Standard use of the VISIA-CR2.2 V3 and TM066 Determination Of Skin Brightness Using The Image Pro Plus Shine Macro Test V2 Unit: Arbitrary unit (AU)
Change from Baseline Skin Features (spot size and color) at 8 weeks
Time Frame: Day 0, Day 56
Skin features: Spot size and color Site: Entire face Procedure: As per WI044 Standard use of the VISIA-CR2.2 V3 and TM038 Clinical Determination of Spot Size and Colour Unit: Color = L\*a\*b\*, Delta E Spot size: volume, count
Change from Baseline Superficial Hydration at 8 weeks
Time Frame: Day 0, Day 56
Skin feature: Superficial hydration Site: Upper cheek - triplicate measurements Procedure: As per WI003 Standard use of the Corneometer CM 825 to measure skin moisture V4. Unit: Arbitrary unit (AU)
Change from Baseline Skin Barrier Integrity at 8 weeks
Time Frame: Day 0, Day 56
Skin feature: Skin barrier integrity Site: Upper cheek - single measurement Procedure: As per WI094 Standard Use of the Delfin Vapometer for Skin Barrier Measurements V1. Unit: g/m2h
Change from Baseline Microbial Level at 8 weeks
Time Frame: Day 0, Day 56
Skin feature: Microbial Level Site: Forehead Procedure: Damp cotton swab Unit: Microbial count by sequencing
Change from Baseline Sebum Level at 8 weeks
Time Frame: Day 0, Day 56
Skin feature: Sebum level Site: Forehead - triplicate measurements Procedure: As per WI005 Standard use of the Sebumeter SM 815 \& MPA 5 to Measure Skin Sebum Levels V2. Unit: µg/cm2
Secondary Outcomes
- Questionnaire on general health and wellbeing(Day 0, Day 28, Day 56)